摘要
低密度脂蛋白胆固醇(LDL-C)升高是动脉粥样硬化的重要独立危险因素。他汀类药物降低LDL-C的水平,预防主要血管事件的作用已得到广泛证实。依折麦布是一种新型降LDL-C药物,其机制是选择性抑制肠胆固醇吸收。其降脂效能已被明确证实,但其对心血管事件的作用尚不明确。近期几项关于依折麦布的临床试验结果陆续发表。现就对于依折麦布有效性及安全性的临床研究最新进展做一系统评述。
Elevated low-density lipoprotein cholesterol（LDL-C） is an independent risk factor of atherosclerosis.Statins can reduce major atherosclerotic vascular events by lowering LDL-C levels.Ezetimibe is a new kind of oral LDL-C lowing drug which selectively inhibits cholesterol absorption in the intestinal tract.It has already been shown to reduce lipid levels in the blood.However,it is not clear whether or not ezetimibe also reduces major atherosclerotic vascular events.Recently,results from several clinical trials about ezetimibe have been published.This review focuses on the results found in recent clinical research of eztimibe.
出处
《心血管病学进展》
CAS
2012年第2期168-171,共4页
Advances in Cardiovascular Diseases
关键词
依折麦布
低密度脂蛋白
动脉粥样硬化
降脂治疗
ezetimibe
low-density lipoprotein cholesterol
atherosclerosis
lipid-lowing therapy
